93281-65-3

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMO-N-TERT-BUTYL-BENZENESULFONAMIDE is used as a pharmaceutical intermediate for the synthesis of various drugs, contributing to the development of new therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 4-BROMO-N-TERT-BUTYL-BENZENESULFONAMIDE is utilized in the production of pesticides, herbicides, and other agrochemicals, playing a role in enhancing crop protection and yield.
Used in Carbonic Anhydrase Inhibition:
4-BROMO-N-TERT-BUTYL-BENZENESULFONAMIDE is used as an inhibitor of carbonic anhydrase, an enzyme involved in the regulation of carbon dioxide and bicarbonate in the body, which can have implications in the treatment of certain medical conditions.
Used in Cancer Research:
4-BROMO-N-TERT-BUTYL-BENZENESULFONAMIDE has been studied for its potential anti-cancer properties, indicating its use in cancer research for developing new therapeutic strategies against various types of cancer.
Used in Anti-Inflammatory Research:
Due to its potential anti-inflammatory properties, 4-BROMO-N-TERT-BUTYL-BENZENESULFONAMIDE is used in research aimed at understanding and treating inflammatory conditions.
It is important to handle 4-BROMO-N-TERT-BUTYL-BENZENESULFONAMIDE with care due to its potential hazards, such as skin and eye irritation, and consider its environmental impacts during use.

InChI:InChI=1/C10H14BrNO2S/c1-10(2,3)12-15(13,14)9-6-4-8(11)5-7-9/h4-7,12H,1-3H3

Upstream product

• 75-64-9 tert-butylamine 
• 98-58-8 4-bromobenzenesulfonyl chloride 
• 701-34-8 4-bromo-benzenesulfonic acid amide 
• 84379-72-6 1,3-dioxoisoindolin-2-yl 3,3-dimethylbutanoate 

Downstream Products

• 701-34-8 4-bromo-benzenesulfonic acid amide 
• 1266477-86-4 4-(5-chloro-4-((5-cyclopropyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)benzenesulfonamide 

Relevant academic research and scientific papers

Organophotoredox-Catalyzed Decarboxylative N-Alkylation of Sulfonamides

We developed an organophotoredox-catalyzed reaction for N-alkylation of sulfonamides with aliphatic carboxylic acid-derived redox active esters as alkylating reagents. Under mild and transition metal-free conditions, a series of functionalized N-alkylated sulfonamides were prepared. This protocol also enabled the functionalization of pharmaceutical drugs bearing a sulfonamide or carboxylic acid moiety. This radical-mediated process allowed the assembly of three components including sulfonamides, redox active esters, and alkenes to yield complex sulfonamides in a one-pot manner.

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical composi

Mtb PKNA/PKNB Dual Inhibition Provides Selectivity Advantages for Inhibitor Design to Minimize Host Kinase Interactions

Drug resistant tuberculosis (TB) infections are on the rise and antibiotics that inhibit Mycobacterium tuberculosis through a novel mechanism could be an important component of evolving TB therapy. Protein kinase A (PknA) and protein kinase B (PknB) are both essential serine-threonine kinases in M. tuberculosis. Given the extensive knowledge base in kinase inhibition, these enzymes present an interesting opportunity for antimycobacterial drug discovery. This study focused on targeting both PknA and PknB while improving the selectivity window over related mammalian kinases. Compounds achieved potent inhibition (Ki ≈ 5 nM) of both PknA and PknB. A binding pocket unique to mycobacterial kinases was identified. Substitutions that filled this pocket resulted in a 100-fold differential against a broad selection of mammalian kinases. Reducing lipophilicity improved antimycobacterial activity with the most potent compounds achieving minimum inhibitory concentrations ranging from 3 to 5 μM (1-2 μg/mL) against the H37Ra isolate of M. tuberculosis.

Five-And-Six-Membered Heterocyclic Compound, And Preparation Method, Pharmaceutical Composition And Use Thereof

A five-and-six-membered heterocyclic compound as represented by general formula I, pharmaceutically acceptable salt, metabolite, metabolic precursors or drug precursors thereof, preparation method, pharmaceutical composition, and use thereof; the five-and-six-membered heterocyclic compound has activity as a Janus kinase (JAK) inhibitor, and can be used to prepare drugs for treating diseases caused by the abnormal activity of kinase, such as cell proliferation diseases like cancer.

PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME

Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11β-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11β-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human- derived 11β-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LAD A), insulin tolerance syndromes, obesity, impaired glucose tolerane (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

Selective angiotensin II AT2 receptor agonists: Benzamide structure-activity relationships

In the investigation of the structure-activity relationship of nonpeptide AT2 receptor agonists, a series of substituted benzamide analogues of the selective nonpeptide AT2 receptor agonist M024 have been synthesised. In a second ser

ARYL SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR

In one embodiment, compounds of the following structure are described, wherein R1 to R7 are described herein. Also provided are methods for preparing these compounds and methods of contraception; treating or preventing fibroids; trea

SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP

The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.

2,3,5-TRISUBSTITUTED PYRIDINES AS INHIBITORS OF CYCLOOXYGENASE-2

The invention encompasses the novel compound of Formula (I) as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula (I). The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula (I).

2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2

The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.